FTRP News and Press, Field Trip Health Ltd. From 12/04/21

Big-cap stocks are generally solid investments, but not all deliver the best returns. Sometimes small-cap stocks are better performers and reward investors with enormous gains. The TSX has a wide selection of potential multi-baggers. Among the names you should keep an eye on are Aura ...

TORONTO, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Field Trip Health Ltd. (TSX: FTRP, FTRP.WT, Nasdaq: FTRP) ("Field Trip"), a global leader in the development and delivery of psychedelic therapies, announced today that management will present at H.C. Wainwright’s 2nd Annual Psychedelics Con...

Psychedelic substances like MDMA and psilocybin show great potential in treating patients with neurological or psychiatric problems. Therefore, drug development companies are showing an increasing interest in the field. Given the industry’s growth potential, Wall Street analysts expect...

The following slide deck was published by Field Trip Health Ltd. in conjunction with this event. For further details see: Field Trip Health (FTRP) Investor Presentation - Slideshow

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Psychedelic drugs could be a major game-changer when it comes to treating mental illness, so loading up on some psychedelic stocks only makes sense. All as psilocybin, LSD, MDMA, and mescaline for example show progress in...

Palm Beach, FL –November 17, 2021 – FinancialNewsMedia.com News Commentary – The uses of Ketamine for a variety of therapies are growing. An expanding number of clinics are offering ketamine infusion therapy for the treatment of mental health disorders and t...

Field Trip Health Ltd. (FTRP) Q2 2022 Earnings Conference Call November 16, 2021 8:30 A.M. ET Company Participants Kathleen Heaney - KCSA Strategic Communications Joseph del Moral - Co-Founder and Chief Executive Officer Ronan Levy - Co-Founder and Executive Chairman Donna Wong - Chief Financ...

After the market closed on Monday, Field Trip Health Ltd. (NASDAQ: FTRP)  reported its second fiscal quarter 2022 results for the second fiscal quarter ending September 30, 2021, and provided a business update. Field Trip earned patient services revenues of $907,816 from ...

Field Trip Health  (NASDAQ:FTRP): FQ2 GAAP EPS of -C$0.23. Revenue of C$0.91M (+911.1% Y/Y) Press Release For further details see: Field Trip Health  reports FQ2 results

Announced plans to advance FT-104, its novel psychedelic compound, to clinic for Treatment-Resistant Depression and Postpartum Depression as the lead indications. Initiated a new pipeline research program focused on discovering novel psychedelics with a reduced cardiovascular risk pro...